Pharma Tech Focus March 2017

Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free.

New data from the UK’s National Institute for Health Research has revealed that all NHS Trusts in England are engaged in clinical research, often in collaboration with industry, to improve outcomes for patients. We examine the practice of clinical research in the public healthcare setting, and ask how patients and the NHS can benefit from a strong research focus.

We also find out more about a new peptide that has been shown to prevent pre-diabetic patients from progressing to diabetes, take a look at the most rapid drug development stories of recent times, and discover how a biotech company is using shark antibodies to treat Alzheimer’s disease.

Plus, we speak to Elsevier R&D Solutions about a project set up to support innovation taking place outside the walls of traditional pharmaceutical companies, and explore the issue of child-friendly drugs through a landmark initiative to distribute tuberculosis medicines for children in Kenya.

In this issue

Critical Clinical Research
New data published by the UK’s National Institute for Health Research has revealed that for the first time ever, all NHS Trusts in England are engaged in clinical research. Abi Millar finds out more.
Read the article.

A Powerful Peptide
An Irish biotech start-up has joined the battle against diabetes with an unexpected weapon of choice: food. Elly Earls meets the company’s founder and chief scientific officer Dr Nora Khaldi to find out more.
Read the article.

Moving Mountains
The speedy review of urgently needed medicines is a key objective of any drug regulatory body, as is maintaining high safety standards. Chris Lo explores how to achieve the right balance between the two.
Read the article.

The Strength of Sharks
Dutch company Crossbeta Biosciences has been granted an exclusive license to shark antibodies. They are considered to have huge disease-specific potential for the treatment of Alzheimer’s disease, but how do they work? Abi Millar finds out.
Read the article.

The Hive
Elsevier’s new incubator project, The Hive, aims to bolster the innovation taking place within pharma and biotech start-ups. Elly Earls catches up with Elsevier and two of the companies involved to find out more.
Read the article.

The Quest for Adherence
Most drugs are developed for adults, which poses real difficulties when the afflicted patients are children. Chris Lo finds out what needs to be done to make sure drugs are child-friendly.
Read the article.

The Keytruda Settlement
On 20 January, Bristol-Myers Squibb and Merck settled a year-long patent fight over Keytruda (pembrolizumab). GlobalData Healthcare analyst, Fenix Leung, reports.
Read the article.

Next issue preview

Japanese pharma company Takeda has announced it will buy Ariad Pharmaceuticals in a deal worth $5.2bn. The move is the latest in a tranche of deals involving Japanese companies setting their sights abroad. We take a look at the deal and find out what it can tell us about the wider market.

We also look into the US’s pharma manufacturing and drug supply chain after President Donald Trump emphasised a new focus on domestic production rather than outsourcing to plants in Asia, find out whether a treatment for Alzheimer’s could be used to regenerate decaying teeth, and explore the medicinal properties of turmeric.

Plus, we ask whether a map of all 1,578 drugs licensed through the FDA could point researchers to uncharted areas of research, and take a closer look at the importance of pharmacodynamics data in the wake of a disastrous clinical trial in France.

Digital magazine FAQ

You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.

You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)